Peroxisome proliferator-activated receptor 3D structures
From Proteopedia
(Difference between revisions)
| Line 10: | Line 10: | ||
**[[4bcr]], [[5hyk]] - hPPARα + ligand<br /> | **[[4bcr]], [[5hyk]] - hPPARα + ligand<br /> | ||
**[[1kkq]] – hPPARα + GW6471 Antagonist + SMRT<br /> | **[[1kkq]] – hPPARα + GW6471 Antagonist + SMRT<br /> | ||
| - | **[[2npa]] - hPPARα + propanoic acid derivative + NCOA1<br /> | ||
**[[2p54]] - hPPARα + NCOA1<br /> | **[[2p54]] - hPPARα + NCOA1<br /> | ||
**[[2rew]] - hPPARα + azetidinone derivative activator<br /> | **[[2rew]] - hPPARα + azetidinone derivative activator<br /> | ||
| Line 17: | Line 16: | ||
**[[3sp6]] - hPPARα + hPPARγ peptide + agonist<br /> | **[[3sp6]] - hPPARα + hPPARγ peptide + agonist<br /> | ||
**[[6kxx]], [[6kxy]] - hPPARα + peptide + agonist<br /> | **[[6kxx]], [[6kxy]] - hPPARα + peptide + agonist<br /> | ||
| - | **[[3et1]] - hPPARα + NCOA1 + indole derivative | + | **[[7c6q]] - hPPARα + peptide + sanguinarine<br /> |
| + | **[[3et1]] - hPPARα + NCOA1 + indole derivative<br /> | ||
| + | **[[6kb7]], [[6kba]] - hPPARα + pyrimidine derivative<br /> | ||
| + | **[[7e5f]], [[7e5g]], [[7e5h]], [[7e5i]] - hPPARα + propanoic acid derivative<br /> | ||
| + | **[[2npa]] - hPPARα + propanoic acid derivative + NCOA1 | ||
| + | **[[6jey]], [[6kax]], [[6kay]], [[6kaz]] ,[[6kb0]], [[6kb1]], [[6kb2]], [[6kb3]], [[6kb4]] ,[[6kb5]], [[6kb6]] ,[[6kb8]], [[6kb9]], [[6lx4]], [[6lx5]], [[6lx6]], [[6lx7]], [[6lx8]], [[6lx9]], [[6lxa]], [[6lxb]], [[6lxc]] - hPPARα + ampiphatic carboxylic acid derivative<br /> | ||
| + | **[[7bpy]], [[7bpz]], [[7bq0]], [[7bq1]], [[7bq2]], [[7bq3]], [[7bq4]] - hPPARα + NCOA1 + ampiphatic carboxylic acid derivative<br /> | ||
| + | **[[6l38]] - hPPARα + benzamide derivative<br /> | ||
| + | **[[6kyp]], [[6l36]], [[6l37]] - hPPARα + benzamide derivative + propanoic acid derivative <br /> | ||
| + | **[[5azt]] - hPPARα (mutant) + NCOA1 peptide<br /> | ||
*'''PPARγ''';Ligand-binding domain 202-475 | *'''PPARγ''';Ligand-binding domain 202-475 | ||
| - | **[[3prg]], [[2qmv]], [[1prg]], [[6l8b]] – hPPARγ<br /> | + | **[[3prg]], [[2qmv]], [[1prg]], [[6l8b]], [[6vzo]] – hPPARγ<br /> |
| - | **[[6fzy]], [[6fzg]] - hPPARγ (mutant) <br /> | + | **[[6fzy]], [[6fzg]], [[6t1s]], [[6vzn]], [[7cxe]] - hPPARγ (mutant) <br /> |
| - | **[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]] – hPPARγ + ligand <br /> | + | **[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]], [[6qj5]], [[6t9c]], [[6tdc]], [[6vzl]], [[7lot]], [[7jqg]] – hPPARγ + ligand <br /> |
**[[4l98]], [[4l96]] - hPPARγ (mutant) + ligand<br /> | **[[4l98]], [[4l96]] - hPPARγ (mutant) + ligand<br /> | ||
**[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | **[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | ||
| Line 31: | Line 39: | ||
**[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | **[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | ||
**[[3osi]], [[3osw]], [[3pba]] - hPPARγ + bisphenol derivative<br /> | **[[3osi]], [[3osw]], [[3pba]] - hPPARγ + bisphenol derivative<br /> | ||
| - | **[[2p4y]], [[3adt]], [[3adu]], [[3adw]], [[3et3]], [[2hfp]], [[3ty0]] - hPPARγ + modulator<br /> | + | **[[2p4y]], [[3adt]], [[3adu]], [[3adw]], [[3et3]], [[2hfp]], [[3ty0]], [[5two]], [[6fzj]], [[6t6b]], [[6y3u]], [[7a7h]] - hPPARγ + modulator<br /> |
**[[2zvt]] - hPPARγ (mutant) + modulator<br /> | **[[2zvt]] - hPPARγ (mutant) + modulator<br /> | ||
**[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]] - hPPARγ + fatty acid activator<br /> | **[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]] - hPPARγ + fatty acid activator<br /> | ||
**[[6jey]] - hPPARγ + fatty acid<br /> | **[[6jey]] - hPPARγ + fatty acid<br /> | ||
| - | **[[6jf0]] - hPPARγ + fluorescent probe<br /> | + | **[[6jf0]], [[7efq]] - hPPARγ + fluorescent probe<br /> |
**[[6mcz]], [[6md0]], [[6md1]], [[6md2]], [[6qj5]], [[6t9c]] - hPPARγ + ligand<br /> | **[[6mcz]], [[6md0]], [[6md1]], [[6md2]], [[6qj5]], [[6t9c]] - hPPARγ + ligand<br /> | ||
**[[6tsg]] - hPPARγ + hormone<br /> | **[[6tsg]] - hPPARγ + hormone<br /> | ||
| - | **[[3ads]], [[3adx]], [[5u5l]], [[4xum]], [[4xuh]], [[4xta]], [[4xld]], [[6d5a]], [[6o67]], [[6o68]] - hPPARγ + anti-inflammatory drug<br /> | + | **[[3ads]], [[3adx]], [[5u5l]], [[4xum]], [[4xuh]], [[4xta]], [[4xld]], [[6d5a]], [[6o67]], [[6o68]], [[7ahj]], [[7awc]], [[7awd]], [[7e0a]] - hPPARγ + anti-inflammatory drug<br /> |
**[[4oj4]] - hPPARγ (mutant) + anti-inflammatory drug<br /> | **[[4oj4]] - hPPARγ (mutant) + anti-inflammatory drug<br /> | ||
**[[3adv]] - hPPARγ + serotonin<br /> | **[[3adv]] - hPPARγ + serotonin<br /> | ||
**[[3k8s]], [[3et0]], [[2yfe]], [[4a4v]], [[4a4w]], [[4jaz]], [[5tto]], [[4pwl]], [[4pvu]], [[5y2t]], [[5y2o]], [[5ugm]], [[6dha]] - hPPARγ + antidiabetic drug<br /> | **[[3k8s]], [[3et0]], [[2yfe]], [[4a4v]], [[4a4w]], [[4jaz]], [[5tto]], [[4pwl]], [[4pvu]], [[5y2t]], [[5y2o]], [[5ugm]], [[6dha]] - hPPARγ + antidiabetic drug<br /> | ||
| - | **[[4o8f]] - hPPARγ (mutant) + antidiabetic drug<br /> | + | **[[4o8f]], [[6vzm]] - hPPARγ (mutant) + antidiabetic drug<br /> |
**[[6md4]] - hPPARγ + oleic acid + antidiabetic drug<br /> | **[[6md4]] - hPPARγ + oleic acid + antidiabetic drug<br /> | ||
**[[6enq]] - hPPARγ + antifibrotic drug<br /> | **[[6enq]] - hPPARγ + antifibrotic drug<br /> | ||
| + | **[[6zly]] - hPPARγ + valine derivative <br /> | ||
*PPARγ complex with polypeptide | *PPARγ complex with polypeptide | ||
| Line 51: | Line 60: | ||
**[[5dwl]], [[5dvc]], [[5dv8]], [[5dv6]], [[5dv3]], [[5dsh]] - hPPARγ + NCOA2 peptide + inhibitor<br /> | **[[5dwl]], [[5dvc]], [[5dv8]], [[5dv6]], [[5dv3]], [[5dsh]] - hPPARγ + NCOA2 peptide + inhibitor<br /> | ||
**[[1zgy]] – hPPARγ + antidiabetic drug + nuclear receptor peptide<br /> | **[[1zgy]] – hPPARγ + antidiabetic drug + nuclear receptor peptide<br /> | ||
| - | **[[2gtk]], [[3qt0]], [[5gtp]], [[5gto]], [[5gtn]], [[6jq7]], [[6izm]], [[6ilq]], [[6ijs]], [[6ijr]], [[6icj]], [[5ycp]], [[5ycn]], [[6ktm]], [[6ktn]] - hPPARγ + NCOA1 peptide<br /> | + | **[[2gtk]], [[3qt0]], [[5gtp]], [[5gto]], [[5gtn]], [[6jq7]], [[6izm]], [[6ilq]], [[6ijs]], [[6ijr]], [[6icj]], [[5ycp]], [[5ycn]], [[6ktm]], [[7cxf]] - hPPARγ + NCOA1 peptide<br /> |
| + | **[[6t1v]], [[7cxg]], [[7cxh]], [[7cxi]], [[7cxj]], [[7cxk]], [[7cxl]] - hPPARγ (mutant) + NCOA1 peptide<br /> | ||
| + | **[[6ktn]] - hPPARγ (mutant) + NCOA1 peptide + leukemia drug<br /> | ||
**[[3cs8]], [[3u9q]]- hPPARγ + PGC-1A peptide<br /> | **[[3cs8]], [[3u9q]]- hPPARγ + PGC-1A peptide<br /> | ||
**[[3cwd]] - hPPARγ + NCOA1-2 peptide<br /> | **[[3cwd]] - hPPARγ + NCOA1-2 peptide<br /> | ||
| - | **[[5two]], [[6izn | + | **[[5two]], [[6izn]], [[6fzj]], [[6t6b]] - hPPARγ + modulating ligand<br /> |
| - | **[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]] - hPPARγ + SRC-1 peptide + modulator<br /> | + | **[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]], [[6fzp]] - hPPARγ + SRC-1 peptide + modulator<br /> |
| + | **[[6fzf]] - hPPARγ (mutant) + NCOA1+ modulator<br /> | ||
**[[4fgy]], [[2prg]] - hPPARγ + antidiabetic drug + NCOA1 peptide<br /> | **[[4fgy]], [[2prg]] - hPPARγ + antidiabetic drug + NCOA1 peptide<br /> | ||
**[[6oni]], [[6pdz]] - hPPARγ + agonist + NCOR peptide<br /> | **[[6oni]], [[6pdz]] - hPPARγ + agonist + NCOR peptide<br /> | ||
**[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | **[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | ||
| + | **[[6izm]], [[6izn]] - hPPARγ + pyridine derivative + NCOA1 peptide<br /> | ||
**[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | **[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | ||
**[[4y29]], [[2fvj]], [[5azt]] - hPPARγ + NCOA1 peptide + ligand<br /> | **[[4y29]], [[2fvj]], [[5azt]] - hPPARγ + NCOA1 peptide + ligand<br /> | ||
| Line 67: | Line 80: | ||
**[[1fm6]] - hPPARγ + antidiabetic drug + retinoic acid receptor α + NCOA2 peptide + retinoic acid<br /> | **[[1fm6]] - hPPARγ + antidiabetic drug + retinoic acid receptor α + NCOA2 peptide + retinoic acid<br /> | ||
**[[3vn2]], [[4hee]], [[4prg]] - hPPARγ + NCOA1 peptide + activator<br /> | **[[3vn2]], [[4hee]], [[4prg]] - hPPARγ + NCOA1 peptide + activator<br /> | ||
| - | **[[6ms7]] - hPPARγ + PGC1 LXXLL<br /> | + | **[[6ms7]] - hPPARγ + PGC1 LXXLL + modulator<br /> |
**[[6dgp]], [[5z6s]], [[5z5s]] - hPPARγ + coactivator peptide<br /> | **[[6dgp]], [[5z6s]], [[5z5s]] - hPPARγ + coactivator peptide<br /> | ||
**[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | **[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | ||
Revision as of 09:52, 9 December 2021
3D Structures of PPAR
Updated on 09-December-2021
